Posts tagged Canaccord


Is it Time to Raise a White Flag on Nike Inc (NKE)? Canaccord Reigns in Expectations for Fiscal 2018

How long will investors still hold out patience for Nike after two years of a “stale innovation pipeline?”

Canaccord More Bullish Than Ever on Quidel Corporation (QDEL); Here’s Why

Analyst bumps up price target on QDEL on back of “sweetened” deal to acquire Alere’s BNP Assay segment.

Oncolytics Biotech Inc. (ONC) Stock Is Significantly De-Risked After End-of-Phase II Meeting with FDA, Cheers Canaccord

Analyst lifts price target on Oncolytics with new clarity from the FDA on Reolysin’s path forward to approval.

Oracle Corporation (ORCL) Is Taking a 4% Dip on FQ2:18 Cloud Growth Outlook; These Analysts Offer a Bullish Take

One top analyst raises price target on Oracle; another analyst believes the worst is now over for the giant.

Synergy Pharmaceuticals Inc (SGYP) Has Encouraging Sustainability Through 2019 Thanks to $300 Million Debt Financing

Synergy protects “financial health” without the sacrifice of extra pressure on share price, says Canaccord.

Lululemon Athletica inc. (LULU) Strong Q2 Numbers Don’t Demonstrate a Rebound: Canaccord

The Risk/Reward Factor of Lulu’s EPS Stalling Growth Does Not Look Too Good, Fears Analyst

Show More